Barcelona November 8, 2012 –Inbiomotion SL, a company focused on the development of biomarkers for the prediction of bone metastasis, today announced the appointment of Dr. Jon Askaa, as non-executive Director, and Dr. Juan Carlos Tercero as Head of Product Development.

Jon is a recognized expert in the development of companion diagnostics. He is currently Chief Medical Officer of Medical Prognosis Institute A/S (Denmark). He was previously Director of companion diagnostics at Genentech where he was responsible for development and implementation of companion diagnostic assays for Genentech’s targeted therapy programs. Before that, he worked at Dako in Denmark and in California and played a pivotal role for the development, launching and implementation of the HercepTest and several other companion diagnostic assays.

Juan Carlos was previously Head of Molecular Medicine of PharmaMar (Madrid, Spain) for eight years where he was responsible of Pharmacogenomics and Translational Research projects focused on the elucidation of mechanism of action and the identification of biomarkers of drug response for clinical development of anti-cancer compounds. Previously he was Director of the Pharmacogenomics Laboratory and Technical Director of PharmaGen (Madrid, Spain) providing DNA fingerprinting services and developing molecular diagnostic kits for detection of tumor markers and infectious diseases using PCR techniques. Before that, he spent 3 years of postdoctoral training in basic biomedical research at the National Institutes of Health (USA).

“Dr. Askaa is a recognized expert in the development of companion diagnostics, notably one of the “fathers” of HercepTest. We are pleased to have his insight and direction in our efforts to develop the first ever companion diagnostic in preventive treatment strategies,” said Joël Jean-Mairet, Chairman of Inbiomotion. “Dr. Askaa’s unique perspective will help guide us as we seek to impact the clinical management and standard of care of early stage cancer patients prone to bone relapse.”

“I’m very pleased to be part of the Inbiomotion board of directors. The very promising biomarker currently under clinical validation by Inbiomotion is expected to have significant clinical utility for identification of cancer patients having high likelihood for development of bone metastatic lesions. The expression of the biomarker is presently validated on a very large group of cancer patients and the outcome of this validation will further substantiate the clinical validity of this biomarker” said Dr. Askaa.

About Inbiomotion

Inbiomotion SL, a spin-out company founded by Dr. Roger Gomis from the Growth Control and Cancer Metastasis group at the Institute for Research in Biomedicine (IRB Barcelona) and ICREA. The company is focused on the development of biomarkers for the prediction of bone metastasis from primary tumor biopsies. In July 2012 Inbiomotion closed a € 2 million Series A financing led by Ysios Capital. Inbiomotion’s proprietary single biomarker codes for a nuclear protein and is able to predict which patients will relapse to the bone. It has been validated with over 900 patient samples in two independent cohorts with three independent techniques (gene expression, IHC and ISH), resulting in negative predictive value of over 95%.

About Ysios Capital
Ysios Capital is an independent venture capital firm providing private equity financing to early and mid-stage human healthcare and biotechnology companies with special focus on pharmaceuticals, diagnostics and medical devices. Ysios launched its first fund, Ysios BioFund I, of 69 million Euros in 2008. Ysios’ investments to date include: Inbiomotion (Barcelona, Spain), MedLumics (Madrid, Spain), AM-Pharma BV (Bunnik, The Netherlands), STAT Diagnostica (Barcelona, Spain), Sabirmedical (Barcelona, Spain), Cardoz (Stockholm, Sweden), Endosense (Geneva), Biovex (now Amgen, Boston) and Cellerix (Madrid, now Tigenix NV NYSE Alternext:TIG).

ysiosdev

See Full Bio